Xbrane Biosciences AB has aquired Primm Pharma

September 2015 — Xbrane Biosciences AB (Xbrane) has acquired Primm Pharma (Primm) for an undisclosed consideration.

Based in Sweden, Xbrane is a biopharmaceutical company specialized in high demand complex generics. This segment has a high entry barrier, driven by high production complexity and the need of specific know-how. The company is looking to extend its offering within the protein production and to gain access to new sales channels through the acquisition of biotech companies offering products and/or services within the protein biosynthesis production chain.

Primm is an international leading company engaged in the manufacturing, marketing and sale of biotech services and products. The company provides advanced custom services like antibodies, peptides, DNA synthesis, DNA sequencing, protein analysis and a variety of pharmacological services based on the use of a state-of-the-art animal facility recently certified under the international GLP standards. Primm was founded in 1990 and is headquartered in Milan, Italy.

Our role in the transaction

Oaklins' teams in Sweden and Italy supported the buyer by scouting the Italian market, identifying the most suitable target, assisting in the LOI formulation and negotiation throughout the process. This deal is another example of seamless cooperation between Oaklins' teams, demonstrating the organization’s added value through its global execution capabilities, industry expertise and contacts.